Gregory Russell Pond
#149,528
Most Influential Person Now
Gregory Russell Pond's AcademicInfluence.com Rankings
Gregory Russell Pondmedical Degrees
Medical
#2859
World Rank
#3301
Historical Rank
Rheumatology
#24
World Rank
#25
Historical Rank
Epidemiology
#547
World Rank
#570
Historical Rank
Gregory Russell Pondphilosophy Degrees
Philosophy
#8210
World Rank
#11545
Historical Rank
Logic
#5240
World Rank
#6624
Historical Rank
Download Badge
Medical Philosophy
Gregory Russell Pond's Degrees
- Bachelors Biology University of California, Berkeley
- Doctorate Medicine University of California, San Francisco
Similar Degrees You Can Earn
Why Is Gregory Russell Pond Influential?
(Suggest an Edit or Addition)Gregory Russell Pond's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. (2002) (1148)
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. (2008) (1061)
- Predictors of infection in rheumatoid arthritis. (2002) (536)
- Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. (2002) (453)
- Measured and estimated GFR in healthy potential kidney donors. (2004) (375)
- Medication Reconciliation at Hospital Discharge: Evaluating Discrepancies (2008) (324)
- A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas (2006) (322)
- Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. (2011) (309)
- Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. (2005) (289)
- Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. (2005) (253)
- Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK (2013) (242)
- Direct Medical Costs Attributable to Osteoporotic Fractures (2002) (233)
- Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. (2007) (222)
- Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. (2007) (208)
- Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy (2005) (201)
- The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. (2002) (186)
- Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study (2008) (181)
- Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer (2006) (173)
- Pharmacist medication assessments in a surgical preadmission clinic. (2007) (173)
- Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. (2015) (158)
- Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. (2006) (155)
- The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. (2014) (147)
- Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. (2007) (146)
- Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. (2014) (143)
- Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. (2002) (138)
- Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. (2006) (138)
- Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. (2005) (136)
- Understanding the attitudes of the elderly towards enrolment into cancer clinical trials (2006) (132)
- Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers. (2007) (131)
- Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. (2005) (129)
- Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. (2016) (125)
- Analysis of treatment practices for elderly cancer patients in Ontario, Canada. (2005) (121)
- Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. (2013) (121)
- Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. (2008) (115)
- Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. (2012) (113)
- Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. (2013) (112)
- Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. (2006) (112)
- Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. (2006) (111)
- Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer (2007) (110)
- Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. (2019) (106)
- Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. (2006) (105)
- Claudin-Low Breast Cancer; Clinical & Pathological Characteristics (2017) (103)
- Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion. (2004) (102)
- A prospective comparison of MRI‐US fused targeted biopsy versus systematic ultrasound‐guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance (2015) (102)
- Cognitive function and fatigue after diagnosis of colorectal cancer. (2014) (102)
- Treating fibromyalgia with a brief interdisciplinary program: initial outcomes and predictors of response. (2001) (101)
- Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. (2006) (98)
- Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. (2011) (95)
- Impact of wait times on survival for women with uterine cancer. (2014) (95)
- Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. (2012) (94)
- Esthesioneuroblastoma: The Princess Margaret Hospital experience (2008) (93)
- Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. (2019) (92)
- Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. (2007) (91)
- Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. (2012) (90)
- Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. (2014) (89)
- The use and toxicity of steroids in the management of patients with brain metastases (2008) (89)
- Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors (2007) (89)
- Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation (2005) (84)
- A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial (2015) (81)
- Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma (2002) (81)
- Do high symptom scores trigger clinical actions? An audit after implementing electronic symptom screening. (2012) (81)
- A Phase 2 study of perifosine in advanced or metastatic breast cancer (2008) (80)
- Penile brachytherapy: results for 49 patients. (2005) (80)
- Long-term urinary sequelae following 125iodine prostate brachytherapy. (2008) (79)
- Randomized phase II trials: inevitable or inadvisable? (2010) (77)
- A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium (2007) (77)
- Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA (2018) (76)
- Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. (2006) (76)
- Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck (2008) (73)
- Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review. (2012) (73)
- C-statistic: A brief explanation of its construction, interpretation and limitations. (2017) (73)
- Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis (2018) (72)
- Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. (2015) (72)
- Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. (2021) (70)
- Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. (2014) (69)
- Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. (2004) (68)
- UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. (2007) (67)
- Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis (2008) (66)
- Epigenetic silencing of miR-145-5p contributes to brain metastasis (2015) (63)
- Neuroendocrine Tumors of the Gastrointestinal Tract: A Decade of Experience at the Princess Margaret Hospital (2008) (62)
- The Decision to Accept Treatment for Osteoporosis Following Hip Fracture: Exploring the Woman’s Perspective Using a Stage-of-Change Model (2002) (62)
- Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. (2011) (60)
- "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. (2002) (59)
- Are family physician visits and continuity of care associated with acute care use at end-of-life? A population-based cohort study of homecare cancer patients (2014) (59)
- Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial (2002) (58)
- Multidisciplinary health care professionals' perceptions of the use and utility of a symptom assessment system for oncology patients. (2011) (56)
- Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. (2016) (56)
- Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. (2016) (55)
- Phase 1 trial design: is 3 + 3 the best? (2014) (55)
- Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital (2006) (54)
- Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. (2004) (53)
- Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. (2006) (53)
- Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study. (2016) (52)
- Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes (2018) (51)
- Early initiation of palliative care is associated with reduced late-life acute-hospital use: A population-based retrospective cohort study (2018) (48)
- Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First‐Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta‐Analysis (2017) (44)
- Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. (2007) (44)
- Improving observer variability in target delineation for gastro-oesophageal cancer--the role of (18F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography. (2008) (43)
- A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer (2019) (42)
- Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology (2018) (42)
- Radiation therapy for Bowen's disease of the skin. (2004) (41)
- Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. (2008) (41)
- Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. (2020) (40)
- Role of fractionated external beam radiotherapy in hemangioblastoma of the central nervous system. (2007) (40)
- Radiographic progression by Prostate Cancer Working Group (PCWG)‐2 criteria as an intermediate endpoint for drug development in metastatic castration‐resistant prostate cancer (2014) (40)
- Factors influencing the use of single vs multiple fractions of palliative radiotherapy for bone metastases: a 5-year review. (2005) (40)
- Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns. (2003) (40)
- Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. (2013) (40)
- Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. (2013) (39)
- A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients (2019) (39)
- Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib (2009) (39)
- Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study (2014) (38)
- A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. (2007) (38)
- Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination (2006) (37)
- Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy (2018) (37)
- Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer (2017) (37)
- A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy. (2019) (37)
- Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. (2008) (37)
- Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. (2013) (36)
- A comparison of patient knowledge of clinical trials and trialist priorities. (2013) (36)
- Prognostic factors for life expectancy in nonagenarians with nonmelanoma skin cancer: implications for selecting surgical candidates. (2002) (36)
- Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. (2012) (36)
- Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. (2006) (35)
- A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma (2014) (35)
- Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy? (2004) (34)
- The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial (2007) (33)
- The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. (2007) (33)
- Rectal-wall dose dependence on postplan timing after permanent-seed prostate brachytherapy. (2006) (32)
- A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia (2006) (32)
- Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer (2019) (32)
- Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial. (2021) (32)
- Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. (2020) (32)
- Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML) (2013) (31)
- Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. (2004) (31)
- Ability of C‐reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel‐based chemotherapy (2012) (31)
- Genitourinary tumors, non-prostate (2012) (31)
- Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. (2005) (30)
- Cytokine levels in patients (pts) with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function (2007) (30)
- A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer (2020) (30)
- Fertility risk discussions in young patients diagnosed with colorectal cancer. (2012) (29)
- Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous‐Cell Carcinoma: Results of a Multicenter Analysis (2017) (29)
- Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. (2014) (28)
- Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer. (2008) (28)
- Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. (2014) (28)
- Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and / or erbB 2 Expressing Adenoid Cystic Carcinoma and Non – Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands (2007) (28)
- Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy; translational biology and rationale for current clinical trials. (2017) (28)
- Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications (2014) (27)
- Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM) (2013) (27)
- Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. (2006) (26)
- The utility of transition zone index in predicting acute urinary morbidity after 125I prostate brachytherapy. (2002) (26)
- Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (2013) (26)
- The Contents and Readability of Informed Consent Forms for Oncology Clinical Trials (2010) (25)
- Posttreatment Complications of Early‐Stage Prostate Cancer Patients: Brachytherapy Versus Three‐Dimensional Conformal Radiation Therapy (2005) (25)
- Association between the Lynch syndrome gene MSH2 and breast cancer susceptibility in a Canadian familial cancer registry (2017) (25)
- Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials (2017) (25)
- Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non-small-Cell Lung Cancer. (2016) (24)
- The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapy (2011) (24)
- Cost effectiveness of a survivorship care plan for breast cancer survivors. (2014) (24)
- Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. (2006) (24)
- Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation (2008) (23)
- A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events (2014) (23)
- Cost-effectiveness of a survivorship care plan for breast cancer survivors. (2011) (23)
- Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study (2018) (23)
- Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials (2011) (22)
- The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. (2016) (22)
- Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. (2017) (22)
- Prognostic Impact of C-Reactive Protein in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis (2014) (21)
- Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. (2008) (21)
- High-sensitivity cardiac troponin I for predicting death in a female emergency department population. (2014) (21)
- Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium (2005) (21)
- The effect of obesity on rectal dosimetry after permanent prostate brachytherapy. (2009) (21)
- Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. (2011) (20)
- Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. (2013) (20)
- Computerized tomographic simulation compared with clinical mark-up in palliative radiotherapy: a prospective study. (2006) (20)
- A Multicenter Phase II Study of “Adjuvant” Irinotecan Following Resection of Colorectal Hepatic Metastases (2005) (20)
- Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. (2012) (20)
- Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer. (2006) (20)
- A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer. (2019) (20)
- A Suggested Prognostic Reclassification of Intermediate and Poor‐Risk Nonseminomatous Germ Cell Tumors (2017) (20)
- Data collection in cancer clinical trials: Too much of a good thing? (2013) (19)
- A phase III randomized trial of the timing of meloxicam with iodine-125 prostate brachytherapy. (2010) (19)
- Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium (2007) (19)
- Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography. (2006) (19)
- The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy (2019) (19)
- Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. (2015) (19)
- Trends in the application of dynamic allocation methods in multi-arm cancer clinical trials (2010) (18)
- Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer (2015) (18)
- Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases (2014) (18)
- Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study (2016) (18)
- Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. (2003) (18)
- A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases (2012) (18)
- Pretreatment neurocognitive function and self‐reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort (2018) (18)
- Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents. (2008) (16)
- A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798) (2008) (16)
- Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer. (2017) (16)
- A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer (2016) (16)
- Age-Related Survival Differences in Patients With Inflammatory Bowel Disease-Associated Colorectal Cancer: A Population-Based Cohort Study. (2019) (16)
- Factors associated with not receiving homecare, end-of-life homecare, or early homecare referral among cancer decedents: A population-based cohort study. (2015) (16)
- Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK). (2020) (16)
- A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium (2009) (16)
- A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy (2012) (16)
- Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab (2018) (16)
- Comparative survival in patients with brain metastases from non-small-cell lung cancer treated before and after implementation of radiosurgery. (2017) (15)
- Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. (2016) (15)
- A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC) (2008) (15)
- A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. (2017) (15)
- Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)‐1 or PD ligand 1 inhibitor therapy (2017) (15)
- Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. (2011) (15)
- First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. (2013) (14)
- Influence of censoring on conclusions of trials for women with metastatic breast cancer. (2015) (14)
- Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study (2018) (14)
- Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. (2013) (14)
- Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. (2014) (14)
- Assessing perfusion changes during whole brain irradiation for patients with cerebral metastases (2005) (14)
- Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. (2016) (14)
- Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. (2016) (14)
- A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer. (2020) (14)
- Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy (2018) (14)
- Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome. (2015) (13)
- Expression of EGFR, HER-2/neu and KIT in germ cell tumours (2010) (13)
- A phase II study of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) (2005) (13)
- LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). (2022) (13)
- Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. (2006) (13)
- Extent of Surgical Resection in Inflammatory Bowel Disease Associated Colorectal Cancer: a Population-Based Study (2021) (13)
- Penile brachytherapy: Results for 60 patients (2007) (13)
- Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy (2015) (13)
- Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. (2014) (13)
- Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead. (2022) (13)
- Phase II multicenter open‐label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies (2005) (13)
- Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. (2011) (12)
- Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. (2014) (12)
- Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. (2012) (12)
- Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population (2018) (12)
- Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. (2015) (12)
- Expanded phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors (2007) (12)
- Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study (2018) (12)
- Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy. (2006) (12)
- Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma. (2021) (12)
- A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors (2007) (12)
- Improving the Quality of Abstract Reporting for Phase I Cancer Trials (2008) (11)
- Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods. (2014) (11)
- Statistical issues in the use of dynamic allocation methods for balancing baseline covariates (2011) (11)
- Quality of preoperative pelvic computed tomography (CT) and magnetic resonance imaging (MRI) for rectal cancer in a region in Ontario: A retrospective population‐based study (2018) (11)
- Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease (2021) (11)
- New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab. (2018) (11)
- Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer (2018) (11)
- Incidence and predictors of prosthetic joint infection following primary total knee arthroplasty: A 15-year population-based cohort study. (2021) (11)
- Independent predictors of prolonged operative time during robotic-assisted radical prostatectomy (2015) (11)
- Factors associated with publication of randomized phase iii cancer trials in journals with a high impact factor. (2014) (11)
- The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer (2020) (11)
- Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC) (2007) (11)
- The wait time creep: changes in the surgical wait time for women with uterine cancer in Ontario, Canada, during 2000-2009. (2013) (10)
- A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer. (2019) (10)
- Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study (2015) (10)
- Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort. (2014) (10)
- Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study. (2016) (10)
- Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. (2020) (10)
- Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle‐Invasive Bladder Cancer (2019) (9)
- Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy. (2017) (9)
- Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer (2018) (9)
- Changes in Soft-Tissue Sarcoma Treatment Patterns over Time: A Population-Based Study in a Country with Universal and Centralized Healthcare (2019) (9)
- Early stopping rules in oncology: considerations for clinicians. (2011) (9)
- High triple‐negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer (2020) (9)
- A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non-Small-Cell Lung Cancer. (2016) (9)
- Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors (2020) (9)
- Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey (2020) (9)
- Is Access to Care Associated With Stage at Presentation and Survival for Melanoma Patients? (2019) (8)
- Validation of a modified VOICES survey to measure end-of-life care quality: the CaregiverVoice survey (2017) (8)
- Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia (2005) (8)
- Chronic obstructive pulmonary disease prevalence and prediction in a high-risk lung cancer screening population (2020) (8)
- Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment. (2020) (8)
- Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer (2018) (8)
- Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. (2021) (8)
- Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients (2019) (8)
- Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Effect of dose escalation on pathological complete response, local recurrence free survival &disease free survival (2004) (8)
- 8506 Cisplatin dose intensity correlates with outcome in patients with locally advanced head and neck squamous cell carcinoma receiving concurrent cisplatin based chemoradiation: a multi-institutional experience (2009) (8)
- The Influence of Mentorship on Research Productivity in Oncology (2007) (8)
- Active surveillance magnetic resonance imaging study (ASIST): Results of a prospective, multicentre, randomized trial (2018) (8)
- Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging (2020) (8)
- A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs) (2005) (8)
- A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer. (2003) (8)
- The impact of chemotherapy-induced cognitive impairment on the psychosocial adjustment of patients with nonmetastatic colorectal cancer. (2012) (8)
- Cardiac and inflammation biomarker profile after initiation of adjuvant trastuzumab therapy. (2013) (7)
- Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. (2017) (7)
- The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, Canada. (2014) (7)
- Genetic Counselling Referral Rates and Uptake of BRCA1 and BRCA2 Testing among Women Diagnosed with Serous Ovarian Cancer in a Tertiary Care Cancer Centre (2013) (7)
- Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer (2016) (7)
- MP-21.03: Penile brachytherapy: results for 60 patients (2007) (7)
- Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function. (2006) (7)
- Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma. (2019) (7)
- A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction (2020) (7)
- Discordance between IHC and ERBB2 mRNA to Determine HER2 Low Status for Breast Cancer. (2022) (7)
- Learning Health System for Breast Cancer: Pilot Project Experience. (2019) (6)
- Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study (2020) (6)
- Influence of statistician involvement on reporting of randomized clinical trials in medical oncology (2013) (6)
- A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer (2012) (6)
- Examining the safety and efficacy of a chemotherapy dosing method in Allogeneic Stem Cell Transplant patients of extreme body size (2009) (6)
- 550 POSTER Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors (2006) (6)
- Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information. (2020) (6)
- Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. (2020) (6)
- Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey (2021) (6)
- Outcome Analysis of Visual Acuity and Side Effect after Ruthenium-106 Plaque Brachytherapy for Medium-sized Choroidal Melanoma (2018) (6)
- Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy. (2013) (6)
- Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration (2021) (6)
- A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574). (2017) (6)
- Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. (2021) (6)
- Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohort (2018) (6)
- Prospective comparison of rectal dose reduction during intracavitary brachytherapy for cervical cancer using three rectal retraction techniques. (2016) (6)
- PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (2017) (6)
- POS-03.96: The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry (2007) (6)
- External validation of the FIRST trial’s simplified frailty score in a population-based cohort (2021) (6)
- Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials. (2018) (6)
- Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer (2021) (5)
- Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort (2019) (5)
- Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: Ontario Clinical Oncology Group DOVE trial (2016) (5)
- Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study. (2020) (5)
- Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. (2015) (5)
- Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer (2020) (5)
- Comparison of absolute benefits of anticancer therapies determined by snapshot and area methods. (2012) (5)
- Effect of Single‐agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration‐resistant Prostate Cancer: Pooled Analysis of Prospective Studies (2017) (5)
- Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer (2019) (5)
- Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. (2011) (5)
- A feasibility study of an internal control methodology using hydrocortisone cream for the management of skin reactions in patients receiving radical radiation therapy for cancers of the head and neck (2006) (5)
- Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study (2021) (5)
- Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey (2021) (5)
- Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial. (2010) (5)
- Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials. (2012) (5)
- Factors associated with acute care use among nursing home residents dying of cancer: a population-based study. (2015) (5)
- Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs). (2019) (4)
- Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). (2011) (4)
- A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC). (2006) (4)
- Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer (2017) (4)
- Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study. (2013) (4)
- Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs). (2019) (4)
- MEDiastinal Irradiation and CArdio-Toxic Effects (MEDICATE): Exploring the Relationship between Cardiac Irradiation and High Sensitivity Troponins. (2019) (4)
- Breast cancer survivors perception of family physician (FP) or specialist as principal provider of routine follow-up care. (2010) (4)
- Intraoperative Sonographically Assisted Radioactive Iodine 125 Plaque Brachytherapy for Choroidal Melanoma (2013) (4)
- Risk Perception Among a Lung Cancer Screening Population. (2021) (4)
- A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma (2016) (4)
- Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial. (2012) (4)
- The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer (2020) (4)
- Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study (2022) (4)
- Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes. (2021) (4)
- Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors (2006) (4)
- The role of PET-CT in treatment decision making for women with locally advanced cervical cancer. (2015) (4)
- Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. (2014) (4)
- Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma (2015) (4)
- Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation (2021) (4)
- Lack of cognitive impairment in long-term survivors of colorectal cancer (2022) (3)
- Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer. (2014) (3)
- Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors (2005) (3)
- Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. (2015) (3)
- Reply to D.J. Stewart (2010) (3)
- Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration‐Resistant Prostate Cancer Treated on SWOG Study S0421 (2017) (3)
- A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia (2021) (3)
- Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC). (2015) (3)
- OCOG-ALMERA: A phase II trial investigating the ability of metformin to chemo-radio-sensitize and prevent recurrence in locally advanced (LA) non-small cell lung cancer (NSCLC)∗ (2016) (3)
- Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study. (2010) (3)
- Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369. (2013) (3)
- Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection (2021) (3)
- Correlation between changes in 2- or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966–2006 (2007) (3)
- Trends in the application of dynamic allocation methods in multiarm cancer clinical trials. (2009) (3)
- Reply to M. Jefford et al and C.T. Stricker et al (2012) (3)
- Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy. (2017) (3)
- P4-12-05: Impact of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) Weight Loss Intervention upon Physical Activity. (2011) (3)
- Genitourinary tumors, prostate (2012) (3)
- Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib. (2014) (3)
- Statistical and analytical approaches for assessing biomarkers: new approaches, new technologies, with the same-old rigor for evaluation. (2012) (3)
- Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival. (2017) (3)
- 5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors. (2019) (3)
- A pragmatic, randomised, multicentre trial comparing 4-weekly vs. 12-weekly administration of bone-targeted agents (denosumab, zoledronate or pamidronate) in patients with bone metastases. (2019) (3)
- Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system (2021) (3)
- Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape. (2017) (3)
- Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. (2015) (3)
- Treatment delay in endometrial cancer. Reply to J. Menczer. (2014) (3)
- Hypofractionated Stereotactic Radiotherapy for the Treatment of Benign Intracranial Meningiomas: Long-Term Safety and Efficacy (2021) (3)
- Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital. (2006) (3)
- Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials. (2010) (3)
- Vasomotor symptoms in early breast cancer—a “real world” exploration of the patient experience (2022) (3)
- Comparison of outcomes between abdominal, minimally invasive and combined vaginal-laparoscopic hysterectomy in patients with stage IAI/IA2 cervical cancer: 4C (Canadian Cervical Cancer Collaborative) study. (2021) (3)
- A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy (2020) (2)
- Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials. (2018) (2)
- A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer (2021) (2)
- 408 A phase II study of erlotinib in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (PHL-002e/NCIC CTG IND.157) (2004) (2)
- Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration‐Resistant Prostate Cancer (2017) (2)
- 2160 : The Addition of 18-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) To CT Based Radiotherapy Planning of Carcinoma of the Esophagus Decreases Both the Intra- And Interobserver Variability of GTV Delineation (2006) (2)
- Impact of Wait Times on Survival for Women With Uterine Cancer (2014) (2)
- A phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) TheraCIM-h-R3 (nimotuzumab) in patients with advanced solid tumors. (2006) (2)
- 357 Impact of Survivorship Care Plans (SCP) On Adherence to Guidelines, Health Service Measures, and Patient-reported Outcomes (PRO): Extended Results of a Multicenter Randomized Clinical Trial (RCT) with Breast Cancer Survivors (2012) (2)
- Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. (2019) (2)
- Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis (2012) (2)
- Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens. (2004) (2)
- Using machine learning to predict individual patient toxicities from cancer treatments (2022) (2)
- Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer (2021) (2)
- Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials (2018) (2)
- Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study. (2006) (2)
- Retrospective analysis of ipilimumab-induced diarrhea and/or colitis: A single centre review. (2017) (2)
- A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer (2021) (2)
- Using Magee equations to predict Oncotype DX recurrence scores: A potential cost and time saving strategy? (2014) (2)
- FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC). (2020) (2)
- Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. (2014) (2)
- Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC). (2011) (2)
- Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study. (2012) (2)
- A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials (2011) (2)
- A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases (2019) (2)
- Accuracy of computerized tomography (CT) imaging in predicting pathologic stage for patients undergoing surgery for transitional cell carcinoma (TCC) of the bladder. (2010) (2)
- Abstract P3-07-16: Comparing surrogates of oncotype Dx recurrence scores in invasive ductal carcinoma: How complicated does it have to be? (2016) (2)
- Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC). (2012) (1)
- Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC). (2020) (1)
- PEDIATRICS CLINICAL RESEARCH (2010) (1)
- Use of a marketing plan for recruitment to a lung cancer screening study. (2017) (1)
- A Phase 3, Multicenter, Randomized Trial to Evaluate the Symptomatic and Quality of Life Improvements in Lung Cancer Patients Receiving External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy (2017) (1)
- Randomized Phase II Trial of Metformin in Combination with Chemoradiotherapy (CRT) in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464) (2020) (1)
- Receptors Tumor Cells to Tumor Necrosis Factor-Family Death Identification of Small Molecules that Sensitize Resistant (2006) (1)
- 202 Relationship of the International Prostate Symptom Score with urinary flow studies, and catherization rates following iodine 125 prostate brachytherapy (2005) (1)
- Routine Imaging or No Routine Imaging, Is That the Question? (2020) (1)
- Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). (2012) (1)
- The unclear zone in phase II clinical trials. (2010) (1)
- Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP). (2011) (1)
- NON-RISK ADAPTED SURVEILLANCE IN STAGE I NONSEMINOMATOUS GERM CELL TUMOURS (NSGCT): IMPROVED RECENT OUTCOMES (2008) (1)
- Prognostic Stratification of Advanced Urothelial Carcinoma (UC) Receiving Second-Line Systemic Therapy Including Time from Prior Chemotherapy (TFPC) as a Prognostic Factor (2012) (1)
- Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis (2022) (1)
- Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse (2021) (1)
- The contribution of multiparametric pelvic and whole body MR to the interpretation of 18F-fluoromethylcholine (FCH) or 68Ga-HBED-CC PSMA-11 (PSMA) PET/CT in the detection of pelvic recurrence or distant metastases in patients with biochemical failure following radical prostatectomy. (2019) (1)
- Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials. (2016) (1)
- Adequacy of data provision and analysis in oncology phase III trials over the past 5 years. (2010) (1)
- Dynamic angiogenic switch as predictor of response to chemotherapy+ bevacizumab in patients with metastatic colorectal cancer. (2016) (1)
- First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC). (2019) (1)
- Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer. (2016) (1)
- Abstract OT1-07-01: MRI screening versus symptom-directed surveillance for brain metastases among patients with triple negative or HER2+ metastatic breast cancer: A pilot study (nct03881605) (2022) (1)
- Analysis of Gross Target Volume (GTV) Observer Variability with FDG-PET and Contrast Enhanced CT in Head and Neck Cancer Using Finite Element Modeling (2005) (1)
- A phase II prospective study of standardized steroid dosing for patients with brain metastases undergoing whole brain radiotherapy (2008) (1)
- Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors. (2016) (1)
- Trial marketing in the Pan-Canadian Early Detection of Lung Cancer Study (2020) (1)
- Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1–3 metastases (2016) (1)
- Oncologic Outcomes of Surgically Treated Cervical Cancer with No Residual Disease on Hysterectomy Specimen: A 4C (Canadian Cervical Cancer Collaborative) Working Group Study (2023) (1)
- Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC). (2011) (1)
- Abstract CT122: Randomized assessment of cisplatin dose interval for ototoxicity in the treatment of locally advanced squamous cell carcinoma of the head and neck undergoing curative concurrent chemoradiotherapy (RADIO) (2019) (1)
- 205 Metformin to modulate AMP-kinase and enhance chemotherapy and radiotherapy in non-small cell lung cancer (2014) (1)
- 191 Phase II trial of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer (2003) (1)
- 47 POSTER A phase II study of Sorafenib (BAY 43-9006) in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal cancer (NPC): final results (2006) (1)
- Comparison of randomized phase II studies (RP2s) and subsequent randomized controlled studies (RCTs) using identical systemic therapies. (2009) (1)
- Metformin for chemo-radio-sensitization of NSCLC. (2016) (1)
- Disparities in surgical management of endometrial cancers in a public healthcare system: A question of equity. (2020) (1)
- A Prospective Study to Evaluate the Need for an Immobilization Device for Treating Modified Mantle Fields in Lymphoma Patients (2005) (1)
- Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. (2016) (1)
- Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada. (2004) (1)
- A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastases (2012) (1)
- Web-Based Asynchronous Tool to Facilitate Communication Between Primary Care Providers and Cancer Specialists: Pragmatic Randomized Controlled Trial (2023) (1)
- Design and analysis of sequential clinical trials using a Markov chain transition rate model with conditional power. (2008) (1)
- Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. (2004) (1)
- A Phase 2 Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-field Boost Radiation Therapy for Brain Oligometastases (2015) (1)
- Neurocognitive function and psychological distress in young adults (YA) with cancer. (2016) (1)
- Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis. (2014) (1)
- Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC). (2016) (1)
- A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients with early-stage breast cancer. (2020) (1)
- Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials (2011) (1)
- Geriatric Assessment and Frailty Changes in Older Patients with Newly-Diagnosed Multiple Myeloma Undergoing Treatment (2019) (1)
- Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma. (2018) (1)
- 875POutcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population (2017) (1)
- A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prOstate cancer (2022) (1)
- Weekly Cyclophosphamide and Alternate Day Prednisone: An Effective, Convenient and Well Tolerated Treatment for Relapsed Multiple Myeloma Following Autologous Stem Cell Transplant. (2004) (1)
- 69 The impact of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) on radiotherapy planning in carcinoma of the esophagus (2006) (1)
- Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy. (2012) (1)
- A comparison of combined immune checkpoint inhibitors (IO) versus vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) in the treatment of advanced clear cell renal cell carcinoma. (2020) (1)
- Feasibility and Effectiveness of Self-Management Education and Coaching on Patient Activation for Managing Cancer Treatment Toxicities. (2023) (1)
- Advancing Academic Cancer Clinical Trials Recruitment in Canada (2021) (1)
- [Consistency in the analysis and reporting of PEPs in oncology randomized controlled trials from registration to publication: a systematic review]. (2012) (1)
- Abstract P3-08-12: Prognostic relevance of neutrophil-to-lymphocyte ratio (NLR) in young women with breast cancer (BC) (2018) (1)
- Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) – a validation study (2016) (1)
- The use of imaging in endometrial cancer prior to potential surgery: Are guidelines being followed? (2021) (1)
- EPCT-11. RURALITY INDEX SCORE AND PEDIATRIC NEURO-ONCOLOGICAL OUTCOME IN ONTARIO (2021) (1)
- Concurrent Pemetrexed/Cisplatin/Radiation for Unresectable Stage IIIA/B Non-Small Cell Lung Cancer: A Phase I/II Study (2007) (1)
- Neurocognitive functions and psychological distress in young adults with cancer (YAC): A prospective, longitudinal study. (2017) (1)
- 212: Cardiac Morbidity Following Radical Thoracic Chemoradiotherapy for Locally Advanced Lung Cancer: A Population-Based Cohort Study (2020) (0)
- Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi). (2018) (0)
- Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer (2012) (0)
- A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798. (2006) (0)
- Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design. (2013) (0)
- Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma. (2022) (0)
- Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual (2005) (0)
- Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials. (2017) (0)
- Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort. (2012) (0)
- Prognostic classification of muscle-invasive bladder cancer (MIBC) following radical cystectomy (RC) alone or with perioperative chemotherapy: Analysis of the U.S. National Cancer Database (NCDB). (2017) (0)
- 140: Indentification of Curculating MIRNA Associated with Development of Castrate Resistance in High-Risk and Biochemically Recurrent Prostate Cancer Patients (2016) (0)
- Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial (2022) (0)
- 162 Radiation dose to the internal pudendal arteries from iodine 125 prostate brachytherapy (2006) (0)
- Abstract P6-05-12: Understanding Patient Perspectives on Window of Opportunity Clinical Trial Participation in Breast Cancer (2023) (0)
- Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer (2023) (0)
- Cardiac Morbidity Following Chemoradiation in Stage III Non-small Cell Lung Cancer Patients: A Population-Based Cohort Study. (2022) (0)
- Do patients with small cell lung cancer (SCLC) who have chemotherapy initiated during a hospital admission benefit from therapy (2014) (0)
- Disparities in the survival of endometrial cancer patients in a public healthcare system: A population-based cohort study. (2020) (0)
- Building a Breast Cancer Learning Health System (2022) (0)
- Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. (2016) (0)
- 58 Radiation target volume delineation (TVD) using FDG-PET and contrast enhanced CT (CECT) for patients with head and neck cancer (2005) (0)
- Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need. (2020) (0)
- SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma. (2020) (0)
- A Prospective Comparative Analysis of 3 Methods of Rectal Retraction for High-Dose-Rate Brachytherapy in Cervical Carcinoma: Effect on Organs at Risk (2014) (0)
- Pattern of relapse after perioperative chemotherapy and radical cystectomy versus radical cystectomy alone in patients with muscle-invasive bladder cancer (MIBC): A multicenter study (2017) (0)
- Early stopping rules employing early progression and response compared with conventional stopping rules in actual phase II trials. (2010) (0)
- The contribution of multiparametric pelvic & whole body MR to interpretation of 18 F-fluoromethylcholine or 68 Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure following radical prostatectomy (2019) (0)
- The impact of synchronous malignancies on survival in patients with early stage curable non-small-cell lung cancer. (2020) (0)
- Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC). (2022) (0)
- Frequency of fertility discussions among young patients diagnosed with colorectal cancer. (2011) (0)
- Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas (2022) (0)
- Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada. (2019) (0)
- F09Gemcitabine and Platinum (GC) chemotherapy alone or with a Taxane (GC-T) as first-line therapy for urothelial cancer (UC): a meta-analysis (2015) (0)
- Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma. (2016) (0)
- Fluororescence in situ hybridization (FISH) gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors (MSGT) treated with lapatinib (2007) (0)
- Oncologists and medical assistance in dying: Where do we stand? (2018) (0)
- 1314 POSTER Quality of Reporting of Modern Randomized Controlled Trials in Oncology (2011) (0)
- MA 20.11 Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population (2017) (0)
- FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study. (2023) (0)
- The impact of preoperative imaging on wait times, surgical approach and overall survival in endometrioid endometrial cancers. (2022) (0)
- Outcomes of Tri-Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer (2018) (0)
- Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status (2004) (0)
- A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens (2016) (0)
- Exclusion of Patients With Brain Metastases in Published Phase III Clinical Trials for Advanced Breast Cancer. (2022) (0)
- Abstract OT1-11-02: A pragmatic, randomised, multicentre trial evaluating the dose timing (morning vs evening) of endocrine therapy and its effects on tolerability and compliance (REaCT-CHRONO Study) (2022) (0)
- Survival in Patients With Brain Metastases From Non-Small Cell Lung Cancer Treated in the Radiosurgery Era (2015) (0)
- 530PANGIOGENIC SWITCH AS PREDICTOR OF RESPONSE TO CHEMOTHERAPY+ BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER. (2014) (0)
- Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients. (2013) (0)
- Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC). (2021) (0)
- The quality of informed consent forms for oncology clinical trials (2008) (0)
- C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy. (2018) (0)
- 6550 POSTER A phase I study of concurrent pemetrexed/cisplatin/radiation for unresectable stage IIIA/B non-small cell lung cancer (2007) (0)
- Do women who self-report cognitive symptoms after breast cancer treatment have more cognitive impairment than those who do not report symptoms? A mechanistic cohort study with functional brain MRI. (2016) (0)
- Response to ‘Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors’ (2021) (0)
- Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors. (2019) (0)
- Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC). (2020) (0)
- PD3-2-5: Preoperative gefitinib in clinical stage I NSCLC (2007) (0)
- A Retrospective Review of Patient Outcomes Following High-Dose-Rate Brachytherapy in the Treatment of Cervical Cancer (2014) (0)
- Abstract OT1-06-01: A randomised trial comparing continuation or de-escalation of bone modifying agents (BMA) in patients treated for over 2 years for bone metastases from either breast or castration-resistant prostate cancer (REaCT-HOLD BMA) (2022) (0)
- Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study. (2015) (0)
- 73 A prospective study to evaluate the need for an immobilization device for treating modified mantle fields in lymphoma patients (2005) (0)
- 105 Cyberknife Stereotactic Radiosurgery for Treatment of Benign Intracranial Meningioma: Long-Term Safety and Efficacy (2019) (0)
- 63 Primary and adjuvant chemoradiotherapy for locally advanced pancreatic cancer: A phase I/II study with long term outcome (2006) (0)
- P1.15-10 Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada (2022) (0)
- Abstract P4-10-29: Identifying novel molecular markers of response to trastuzumab in metastatic breast cancer (2020) (0)
- Essential Statistical Tests (2019) (0)
- 596 Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration (2015) (0)
- Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer. (2013) (0)
- Targeting tumor metabolism to improve radio-sensitivity in non-small cell lung cancer (NSCLC) (2016) (0)
- Oral Session 2-The Continuum from Translation to Implementation (2013) (0)
- Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study (2018) (0)
- Abstract PO-142: Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer (2022) (0)
- Abstract P6-12-11: A randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer (2017) (0)
- Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study. (2014) (0)
- Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study). (2022) (0)
- P2.15-31 The Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014 (2018) (0)
- Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors. (2020) (0)
- Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy. (2020) (0)
- P021 A pragmatic randomised, multicentre trial evaluating the dose timing (morning vs evening) of endocrine therapy for early breast cancer (REaCT-CHRONO Study) (2023) (0)
- A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer (2021) (0)
- Suggested reclassification strategy applied to intermediate and poor risk nonseminomatous germ cell tumors (NSGCT): A two-institution combined analysis. (2016) (0)
- 867POUTCOMES WITH CISPLATIN-BASED FIRST-LINE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA (UC) FOLLOWING PREVIOUS PERIOPERATIVE CISPLATIN-BASED THERAPY. (2014) (0)
- GERIATRIC ASSESSMENT CHANGES IN OLDER PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA UNDERGOING TREATMENT (2019) (0)
- First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC). (2019) (0)
- EP618 The use of preoperative imaging in endometrial cancer: are ontario physicians following GOC guidelines? (2019) (0)
- Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). (2012) (0)
- The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario, Canada Between 2009-2017. (2021) (0)
- External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC). (2014) (0)
- Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial) (2022) (0)
- Phase I Targeted CombinationTrial of Sorafenib and Erlotinib in Patients with Advanced SolidTumors (2007) (0)
- Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC). (2015) (0)
- MA05.06 Diagnosis of Chronic Obstructive Pulmonary Disease in Lung Cancer - A Population Based Study (2017) (0)
- Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis. (2015) (0)
- Inconsistencies among lists of cautioned/prohibited drugs in oncology phase I and phase II trials. (2010) (0)
- Regularly scheduled physical examinations and the detection of breast cancer recurrences (2023) (0)
- A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas. (2014) (0)
- Abstract P5-04-04: Does reducing the frequency of regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer? (2023) (0)
- Thyroid hormone receptor a in breast cancer: prognostic and therapeutic implications Katarzyna J. JerzakJessica CockburnGregory R. PondKathleen I. Pritchard • Steven A. NarodSukhbinder K. Dhesy-ThindAnita Bane (2015) (0)
- 95 Stereotactic program development in the management of meningioma (2005) (0)
- Predictors of Blood Transfusion Requirements in Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. (2006) (0)
- Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide. (2017) (0)
- Abstract PD11-02: PD11-02 A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 in Early Stage Breast Cancer: the INVINCIBLE Trial (2023) (0)
- Abstract P2-13-04: Inclusion of Patients with Leptomeningeal Disease in Phase III Randomized Clinical Trials of Patients with Advanced Breast Cancer, Lung Cancer, and Melanoma: A Systematic Review (2023) (0)
- Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada (2022) (0)
- Quality of Life Assessment in Older Patients with Newly-Diagnosed Multiple Myeloma (2019) (0)
- Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs). (2011) (0)
- A phase II study of UCN-01 in combination with topotecan in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a study of the Princess Margaret Hospital phase II consortium (PMH-C).: PD6-1-7 (2007) (0)
- Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT). (2023) (0)
- Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration. (2020) (0)
- Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study (2021) (0)
- Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC). (2015) (0)
- Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab (2017) (0)
- Predictors of Minimally Invasive Surgery for Uterine and Cervix Cancer from 2000 – 2017 in Ontario, Canada (2020) (0)
- Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors. (2014) (0)
- Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors. (2015) (0)
- Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. (2022) (0)
- Are O lder C ancer P atients B eing R eferred t o O ncologists? A M ail Q uestionnaire o f O ntario P rimary C are P ractitioners to E valuate T heir R eferral P atterns (2003) (0)
- Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer. (2006) (0)
- Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC). (2016) (0)
- A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer. (2011) (0)
- Do high symptom scores trigger clinical actions by providers? Assessing the effect of standardized symptom screening. (2011) (0)
- 2413: Multiobserver Variabilty in Abnormal Lymph Node Identification With FDG-PET and Contrast Enhanced CT in Head and Neck Cancer: Qualitative Analysis and Potential Clinical Significance (2006) (0)
- Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis (2016) (0)
- Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC). (2013) (0)
- 100: The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario between 2009-2017 (2021) (0)
- Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib (2005) (0)
- Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies (2004) (0)
- Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy. (2015) (0)
- The quality of phase I trial (P1T) abstracts submitted to ASCO meetings (2016) (0)
- Quantitative immunohistochemical (IHC) assessment of ataxia-telangiectasia mutated (ATM) in estrogen receptor (ER) negative early breast cancer (BC). (2012) (0)
- 122 A Comparison of Radiation Techniques in Patients Treated with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (2019) (0)
- Isamed Journals (2017) (0)
- P-0215 Patient Factors Involved in Referral for Lynch Syndrome (2012) (0)
- Preemptive therapy with ganciclovir and short-course intravenous immunoglobulin does not prevent recurrent cytomegalovirus infection (CBMTG-102 study) (2005) (0)
- Abstract A100: Seamless phase I/II clinical trials in oncology: retrospective analysis of the last 7 years (2018) (0)
- BRACHY: A Randomized Trial to Evaluate Symptom Improvement in Advanced Non-Small Cell Lung Cancer treated with External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy. (2023) (0)
- Subject Index Vol. 37, 2009–10 (2011) (0)
- Abstract P6-09-02: Pre-treatment cognitive function (CF) in women with locally advanced breast cancer (LABC) and in healthy controls. (2012) (0)
- Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study (2022) (0)
- Correlation of deviation from intended cisplatin (CDDP) dose intensity with outcome in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) receiving concurrent chemoradiation (CRT) (2008) (0)
- 865PTHE SIGNIFICANCE OF COMPLETE RESPONSE (CR) IN PATIENTS RECEIVING SALVAGE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA (UC). (2014) (0)
- Contents Vol. 37, 2014 (2014) (0)
- Abstract A124: Characterization of claudin-low breast cancers (2013) (0)
- Assessment of galectin-3, N-terminal pro-brain natriuretic peptide and inflammatory cytokines in patients with myocardial injury after initiation of adjuvant trastuzumab therapy (2014) (0)
- Cardiac Morbidity Following Radical Thoracic Chemoradiotherapy for Locally Advanced Lung Cancer: A Population-Based Cohort Study (2020) (0)
- Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL) (2022) (0)
- Metformin-A Thought-Provoking Addition to Anticancer Therapies-Reply. (2021) (0)
- A randomized controlled trial to evaluate the impact of an educational DVD on cancer patients considering participation in a phase I clinical trial. (2006) (0)
- Will COVID-19 directives to reduce regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer? (2022) (0)
- Abstract PS14-18: A physician survey evaluating real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast cancer (2021) (0)
- SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma. (2022) (0)
- Androgen pathway manipulation and outcome in elderly men with non-small cell lung cancer: A population-based study from Ontario, Canada. (2014) (0)
- The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement. (2019) (0)
- Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study. (2018) (0)
- A randomised controlled trial evaluating two cognitive rehabilitation approaches for cancer survivors with perceived cognitive impairment (2022) (0)
- Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC). (2012) (0)
- The Pathologic and Treatment Factors Associated With Recurrence in Stage IA Serous Adenocarcinoma of the Uterus. (2016) (0)
- 41 Does exercise improve progression free survival (PFS) and quality of life (QOL) in patients with glioblastoma? A trial in progress (2018) (0)
- Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC). (2018) (0)
- Association of Rectal Dosimetry and Toxicity With Body Mass Index After Permanent Brachytherapy for Low Risk Prostate Cancer (2007) (0)
- The Relationship of International Prostate Symptom Score with Urinary Flow Studies, and Catheterization Rates Following Iodine 125 Prostate Brachytherapy (2005) (0)
- Types of Variables and Distributions (2018) (0)
- Prognostic ability of HR-QoL parameters in metastatic renal cell carcinoma (mRCC) (2016) (0)
- Methods to improve the estimation of time‐to‐event outcomes when data is de‐identified (2018) (0)
- Overall survival of patients with chronic obstructive pulmonary disease receiving immunotherapy for non-small cell lung cancer: A population-based analysis in Ontario, Canada. (2022) (0)
- 382 POSTER Comparison of phase I trial (P1T) abstract quality between the EORTC-NCI-AACR and ASCO meetings (2008) (0)
- Trajectory of Symptoms after Autologous Stem Cell Transplant Among Patients with Multiple Myeloma: A Population-Based Study (2020) (0)
- 228: Pathologic and Treatment Factors Associated with Recurrence in Stage IA Serous Adenocarcinoma of the Uterus (2016) (0)
- 13PA randomized, double-blind, placebo-controlled window of opportunity trial evaluating clinical effects of high dose vitamin D in patients with breast cancer (2017) (0)
- Abstract P2-11-10: Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial (2023) (0)
- Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs) (2007) (0)
- Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC). (2021) (0)
- Contents Vol. 37, 2009–10 (2011) (0)
- Expression of thyroid hormone receptor alpha (THRα) isoforms in triple negative breast cancer (TNBC). (2015) (0)
- P2.11-23 Risk Perception Among a Lung Cancer Screening Population (2018) (0)
- Az erlotinib és cisplatin I/II. fázisú vizsgálata kiújuló vagy áttétes fej-nyaki laphámrákokban: a Princess Margaret Hospital Phase II Consortium és a National Institute of Canada Clinical Trials Group Study (2013) (0)
- 116P Any regression of tumor (ART) as an intermediate endpoint in patients (pts) treated with immune checkpoint inhibitors (ICI): A pan-cancer analysis (2022) (0)
- Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC). (2015) (0)
- 77: Dosimetric Comparison of Conformal Radiation Therapy (Crt), Imrt and Vmat for Esophageal Cancer Treated with External Radiation (2020) (0)
- Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative. (2022) (0)
- Is Symptom Burden Associated with Health Care Utilization: A Longitudinal Population-Based Cohort Study of Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma (2021) (0)
- CLINICAL INVESTIGATION Brain ROLE OF FRACTIONATED EXTERNAL BEAM RADIOTHERAPY IN HEMANGIOBLASTOMA OF THE CENTRAL NERVOUS SYSTEM (0)
- RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS (2018) (0)
- POS-03.95: Long-term urinary sequellae following iodine 125 prostate brachytherapy (2007) (0)
- Does Modern Mediastinal Irradiation Cause Acute Subclinical Cardiac Toxicity? The Final Results of the MEDICATE Study (Mediastinal Irradiation and Cardio-Toxic Effects) (2018) (0)
- Symptom Burden in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Population-Based Study of Patient-Reported Outcomes (2020) (0)
- P-526 Phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer (NSCLC) (2005) (0)
- Investigating the appropriateness of different concordance measures in a time‐to‐event setting (2020) (0)
- A randomized study comparing physician-directed or fixed-dose dexamethasone replacement following incomplete steroid premedication for docetaxel chemotherapy. (2019) (0)
- Abstract PD6-04: Lifestyle intervention study (LISA) in early breast cancer (BC): An RCT of the effects of a telephone-based weight loss intervention (with educational materials) vs educational materials alone on disease-free survival (DFS) (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gregory Russell Pond?
Gregory Russell Pond is affiliated with the following schools:
